University Hospital in New Jersey Purchases MicroThermX® Microwave Ablation System from BSD Medical

  University Hospital in New Jersey Purchases MicroThermX® Microwave Ablation
  System from BSD Medical

Business Wire

SALT LAKE CITY -- May 22, 2013

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, announced today that the Company has sold a MicroThermX^® Microwave
Ablation System (MicroThermX^®) to University Hospital (UH) in New Jersey. UH
is the primary teaching hospital for New Jersey Medical School and other
Newark-based healthcare programs and thus is uniquely positioned to help
advance extraordinary scientific discoveries. UH is a model venue for the
integration of education and research to promote breakthrough discoveries in
healthcare. University Hospital is broadly recognized among the nation’s best
hospitals. Approximately one-third of the patients at University Hospital come
from outside Essex County and the U.S., reflecting the breadth of services and
expertise available at UH.

"We are excited to have state-of-the-art ablation treatment with the
MicroThermX^® available in this high-profile, prestigious hospital," stated
Sam Maravich, BSD's Vice President of Sales and Marketing. “UH is a referral
center for patients throughout the Northeast."

About the MicroThermX^® Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design of
the MicroThermX ^ is the first of its kind that allows delivery of higher
power levels using a single generator. The MicroThermX ^ utilizes proprietary
synchronous phased array technology that was developed and patented by BSD to
provide a wide range of uniform zones of ablation. The MicroThermX includes
advanced, high-end disposables (SynchroWave antennas) that are used in each
diseased soft tissue (tumor) ablation treatment, which provides a significant
ongoing revenue stream. The soft tissue (tumor) ablation world market
potential is estimated to exceed $2.3 billion. The U.S. Food and Drug
Administration (FDA) has granted the Company a 510(k) clearance to market the
MicroThermX for ablation of soft tissue. BSD has also received CE Marking for
the MicroThermX System, which allows BSD to market the MicroThermX ^ in
Europe. CE Marking is also recognized in many countries outside of the EU,
providing BSD the ability to market the MicroThermX ^ to a number of
international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the expected use of proceeds relating to the
recently completed offering. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.